• Genentech Inc., a South San Francisco-based member of the Roche Group, reported that Avastin (bevacizumab) plus radiation and temozolomide chemotherapy demonstrated a significant improvement in progression-free survival, a co-primary endpoint of the Phase III AVAglio study.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST